Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a Chinese pharmaceutical company, has disclosed that its Chairman and General Manager, Ding Zhao, is under investigation by the China Securities Regulatory Commission (CSRC) for suspected short-term trading of the company’s shares. The matter is a personal inquiry into Mr. Ding Zhao and is not expected to significantly affect the functioning of the company’s board or its day-to-day operations, according to a statement from Huiyu Pharma. Mr. Ding Zhao is committed to fully cooperating with the authorities.
This development follows an apology letter issued by Huiyu Pharma in April, in which the company admitted to short-term trading activities involving Ding Zhao and his relatives. Established in 2021, Huiyu Pharma specializes in the research, development, manufacturing, and marketing of anti-tumor injections. Its product portfolio includes a range of medications such as pemetrexed, docetaxel, azacitidine, paclitaxel, oxaliplatin, bendamustine, irinotecan, bortezomib, and palonosetron, all of which are part of China’s national volume-based procurement program.- Flcube.com
